Surveying saccular system with VEMP before and after intratympanic dexamethasone in patients with unilateral definite Meniere disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013030412691N1

Enrollment

Registered

2013-03-17

Start date

2012-06-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere Disease. Ménière disease

Interventions

Following local anesthesia with Lidocaine, intratympanic dexamethasone will be injected in antrosuperior of tympanic membrane, trice during one week period.

Treatment - Drugs

Following local anesthesia with Lidocaine, intratympanic dexamethasone will be injected in antrosuperior of tympanic membrane, trice during one week period

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:Unilateral definite Meniere Disease presenting with unresponsive vertigo attacks to medical treatment. Exclusion criteria: CNS disease, Neuromuscular disease, conductive hearing loss, bilateral Meniere Disease, patients with only hearing state

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Vertigo. Timepoint: Every 6 weeks for 6 months to one year. Method of measurement: VEMP, Vertigo scale.	—

Secondary

Measure	Time frame
Side effects. Timepoint: during each visit. Method of measurement: ear eamination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Nezhadian, MD

ENT Research Center

dr.fnezhadian@gmail.com+98 21 6670 1768

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026